SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Lefkowitz Steven W
(Last) (First) (Middle)
C/O CORMEDIX INC.
745 ROUTE 202-206, SUITE 303
(Street)
BRIDGEWATER NJ US 08807
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Interim Chief Financial Office
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2013
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/22/2013 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value per share 08/22/2013 A 5,800 A $0.95 61,072 D
Common Stock, par value $0.001 per share 10,000 I Reporting Person's Wife(8)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to purchase Common Stock) $3.4375 08/20/2013 P 5,000 08/20/2013 03/24/2015 Common Stock, $0.001 par value per share 5,000 $0.09 5,000 D
Stock Option (right to buy) $0.9 (1) 03/20/2023 Common Stock, $0.001 par value per share 120,000 120,000 D
Stock Option (right to buy) $0.68 (2) 12/05/2022 Common Stock, $0.001 par value per share 150,000 150,000 D
Senior Convertible Note (convertible into Common Stock) $0.35 11/13/2012 11/13/2013 Common Stock, $0.001 par value per share 42,857 0 D
Warrant (right to purchase Comm Stock) $0.4 11/13/2012 11/13/2017 Common Stock, $0.001 par value per share 37,500 0 D
Senior Convertible Note (convertible into Common Stock)(3) $0.35 09/20/2012 09/20/2013 Common Stock, $0.001 par value per share 100,000 0 I(3) Wade Capital Corporation
Warrant (right to purchase Common Stock)(3) $0.4 09/20/2012 09/20/2017 Common Stock, $0.001 par value per share 87,500 0 I(3) Wade Capital Corporation
Stock Option (right to buy) $0.29 (4) 01/06/2022 Common Stock, $0.001 par value per share 30,000 30,000 D
Stock Option (right to buy) $1.1 (5) 08/11/2021 Common Stock, $0.001 par value per share 30,000 30,000 D
Warrant(6) $3.4375 (7) 03/24/2015 Common Stock, $0.001 par value per share 19,536 19,536 D
Explanation of Responses:
1. These options vest quarterly over two years beginning June 13, 2013.
2. These options vest as follows: fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.
3. The reporting person beneficially owns these securities through Wade Capital Corporation (an entity for which he has voting and investment control).
4. The options vest in full on the first anniversary of the date of grant.
5. The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
6. (Right to buy Common Stock, $0.001 par value per share)
7. The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.
8. This report does not reflect 20,000 shares underlying a warrant which warrant was incorrectly reported as being owned by the reporting person's wife in a Form 3 filed on August 15, 2011.
/s/ Alexander M. Donaldson by Power of Attorney 08/23/2013
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.